TL;DR
This study reveals that T<sub>H</sub>17 cells, crucial for immunity and inflammation, rely on mitochondrial respiration (OXPHOS) for survival and persistence. By forcing T<sub>H</sub>17 cells to use OXPHOS, researchers found they become resistant to apoptosis, a key factor in their long-term presence in tissues and anti-tumor immunity.
What Problem Does This Paper Address?
T<sub>H</sub>17 cells are vital for fighting infections and play roles in chronic inflammatory diseases and anti-tumor responses. While known to be long-lived, the precise metabolic mechanisms governing their survival and persistence, especially their resistance to programmed cell death (apoptosis), have been unclear. Previous research suggested T<sub>H</sub>17 cells primarily use glycolysis, but this didn't fully explain their in vivo behavior. This paper addresses the gap in understanding how T<sub>H</sub>17 cells' metabolic state, specifically their reliance on OXPHOS, influences their apoptotic resistance and ultimately their longevity and function in the body.
Methods
The researchers developed a novel in vitro cell culture system to mimic the metabolic state of T<sub>H</sub>17 cells found in vivo. This involved culturing naïve CD4 T cells in glucose-free media supplemented with galactose, forcing them to rely on mitochondrial oxidative phosphorylation (OXPHOS) instead of glycolysis. They then employed a suite of techniques to analyze these cells:
- Seahorse Flux Analysis: To measure cellular respiration (OCR) and glycolysis (ECAR), assessing metabolic fitness and spare respiratory capacity.
- Metabolomics: Using liquid chromatography-coupled tandem mass spectrometry (LC-MS/MS) to profile the metabolic landscape of glycolytic vs. OXPHOS T<sub>H</sub>17 cells, including stable isotope tracing with 13C-labeled nutrients.
- RNA Sequencing (RNA-seq): To analyze gene expression differences, particularly focusing on genes involved in apoptosis.
- Flow Cytometry: To assess cell viability, apoptosis (Annexin V/7-AAD staining), cytokine production (IFN-γ, IL-17A), transcription factor expression (RORγt, T-bet, Foxp3), and mitochondrial content (MitoTracker Green).
- Western Blotting: To quantify the expression of key pro- and anti-apoptotic proteins (BCL-2 family).
- Competitive Co-transfer Experiments: Mixing glycolytic and OXPHOS T<sub>H</sub>17 cells and transferring them into mice to assess their relative survival, persistence, and proliferation in vivo.
- Tumor Studies: Transferring T<sub>H</sub>17 cells into tumor-bearing mice to evaluate their impact on tumor growth and the tumor microenvironment.
Datasets
The study utilized mouse models (C57BL/6, B6.SJL, RAG2-/- mice) and their immune cells. No new benchmark datasets were introduced; rather, the study generated novel experimental data through the described methods.
Key Insights and Ideas
- Metabolic Flexibility vs. Specialization: T<sub>H</sub>17 cells can differentiate and function using either glycolysis or OXPHOS, but OXPHOS confers a distinct survival advantage.
- OXPHOS as an Anti-Apoptotic Switch: Forcing T<sub>H</sub>17 cells to use OXPHOS leads to a significant upregulation of anti-apoptotic proteins (BCL-XL, MCL-1) and downregulation of pro-apoptotic proteins (BIM), making them more resistant to cell death.
- Mitochondrial Fitness and Longevity: OXPHOS promotes increased mitochondrial mass and fitness, which directly correlates with enhanced T<sub>H</sub>17 cell survival and persistence, mirroring characteristics of long-lived memory CD8 T cells.
- In Vivo Relevance: The in vitro findings on OXPHOS-driven apoptotic resistance and persistence were validated in vivo through co-transfer experiments and tumor models, demonstrating that OXPHOS T<sub>H</sub>17 cells outcompete glycolytic ones.
- Therapeutic Potential: The findings suggest that manipulating T<sub>H</sub>17 cell metabolism, specifically promoting OXPHOS, could be a strategy to enhance anti-tumor immunity or modulate inflammatory responses.
Key Results
- T<sub>H</sub>17 cells cultured in galactose (forcing OXPHOS) exhibited higher oxygen consumption rates (OCR), lower extracellular acidification rates (ECAR), and increased spare respiratory capacity (SRC) compared to glucose-cultured (glycolytic) cells.
- OXPHOS T<sub>H</sub>17 cells showed significantly increased resistance to apoptosis induced by various stimuli (TBHP, staurosporine, Fas) compared to glycolytic T<sub>H</sub>17 cells.
- This apoptotic resistance was linked to increased expression of anti-apoptotic BCL-XL and MCL-1, and decreased expression of pro-apoptotic BIM in OXPHOS T<sub>H</sub>17 cells.
- In competitive co-transfer experiments, OXPHOS T<sub>H</sub>17 cells persisted at higher frequencies in blood, lymph nodes, spleen, and lamina propria compared to glycolytic T<sub>H</sub>17 cells.
- In a tumor model, mice receiving OXPHOS T<sub>H</sub>17 cells showed slower tumor growth, correlating with better persistence of these cells in the tumor microenvironment.
Limitations and Future Work
- In Vitro vs. In Vivo Mimicry: While the galactose-based system effectively mimics in vivo OXPHOS use, it's still an in vitro model. The authors acknowledge the challenges of studying metabolism directly in vivo, especially in rare immune cell populations.
- Unresolved Signaling Cues: The precise metabolic and signaling cues that promote OXPHOS in T<sub>H</sub>17 cells in vivo remain unresolved.
- Specificity of OXPHOS Effects: It's unclear if the anti-apoptotic profile mediated by OXPHOS is specific to T<sub>H</sub>17 cells or a general phenomenon in OXPHOS-dependent T cells.
- Mechanisms of TME Modulation: While OXPHOS T<sub>H</sub>17 cells improved anti-tumor immunity, the exact mechanisms by which they modulate the tumor microenvironment (TME) beyond persistence warrant further investigation.
- Therapeutic Translation: The study highlights the potential for targeting OXPHOS in T<sub>H</sub>17-driven diseases, but further research is needed to translate these findings into clinical applications.
Summary updated